Stapled Peptides Modulating Mdm2 and Chip Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective agents for modulating the biological functions of E3 ubiquitin-protein ligases Mdm2 and Chip, particularly in binding to these proteins or their fragments, which are crucial for various biological processes and therapeutic applications.
Innovation Solution
Development of stapled peptides that can bind to Mdm2 or Chip, comprising specific amino acid residues and structural features such as D-amino acids and staples, allowing for modulation of their activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional peptide agents are used to bind Mdm2 or Chip, then the binding activity is limited, but the structural complexity and stability are insufficient
Solution Approach 1:
The patent applies parameter changes by substituting L-amino acids with D-amino acids in the peptide sequence, which fundamentally alters the stereochemical parameters of the peptide. This substitution maintains the ability to bind Mdm2 or Chip while significantly improving proteolytic stability and resistance to degradation, thereby resolving the contradiction between binding activity and stability.
Solution Approach 2:
The patent creates composite structures by combining stapled peptide motifs with D-amino acid residues. The staple (a chemical crosslink) forms a composite structure that locks the peptide into a specific conformation, while D-amino acids provide stability. This composite approach enhances both binding activity through conformational locking and stability through protease resistance.
2Reliability
If peptide sequence is optimized for binding affinity, then binding activity improves, but the complexity of peptide synthesis and characterization increases
Solution Approach 1:
The patent segments the peptide design into modular components: a core binding sequence that interacts with Mdm2 or Chip, D-amino acid residues positioned for stability, and staple locations that lock the conformation. This segmentation allows systematic optimization of binding affinity while managing synthesis complexity through a structured design approach.
Solution Approach 2:
By systematically changing parameters such as staple position (e.g., i, i+3, i+4, i+7), D-amino acid placement, and amino acid side chain properties, the patent optimizes binding affinity while maintaining a manageable synthesis complexity. The modular parameter changes allow for rational design rather than exhaustive screening.
3Reliability
If stapled peptides are designed with multiple staples and D-amino acids, then binding activity and stability improve, but the manufacturing complexity increases
Solution Approach 1:
The patent optimizes manufacturing ease by carefully selecting parameters such as the number of staples (typically 1-3), their positions in the sequence, and the placement of D-amino acids. These parameter choices balance binding activity and stability improvements against the increased complexity of synthesis, avoiding excessive manufacturing difficulty while achieving the desired performance.
Data Source
AI summary
Among other things, the present disclosure provides various useful agents. In some embodiments, provided agents can bind to MDM2. In some embodiments, provided agents can bind to CHIP. In some embodiments, the present disclosure provides technologies for modulating MDM2 functions. In some embodiments, the present disclosure provides technologies for modulating CHIP functions. In some embodiments, the present disclosure provides technologies for preventing or treating conditions, disorders or diseases.